Referencias seleccionadas para ampliar conocimientos:

1.- Jordan C. Historical perspective on hormonal therapy of advanced breast cancer. Clin Ther. 2002;24 Suppl A:A3-16.

2.- Jefcoate CR, Liehr JG, Santen RJ, Sutter TR, Yager JD, Yue W, Santner SJ, Tekmal R, Demers L, Pauley R, Naftolin F, Mor G, Berstein L. Tissue-specific synthesis and oxidative metabolism of estrogens. J Natl Cancer Inst Monogr. 2000;(27):95-112

3.- Yager JD. Endogenous estrogens as carcinogens through metabolic activation.J Natl Cancer Inst Monogr. 2000;(27):67-73.

4.- Simpson ER, Clyne C, Speed C, Rubin G, Bulun S. Tissue-specific estrogen biosynthesis and metabolism. Ann N Y Acad Sci. 2001;949:58-67.

5.- Lonning PE, Kragh LE, Erikstein B, Hagen A, Risberg T, Schlichting E, Geisler J. The potential for aromatase inhibition in breast cancer prevention. Clin Cancer Res. 2001;7(12 Suppl):4423s-4428s

6.- Henderson E, Feigelson HS. Hormonal carcinogenesis. Carcinogenesis. 2000;21(3):427-33.

7.- Persson I. Estrogens in the causation of breast, endometrial and ovarian cancers - evidence and hypotheses from epidemiological findings. J Steroid Biochem Mol Biol. 2000;74(5):357-64.

8.- Grover PL, Martin FL. The initiation of breast and prostate cancer. Carcinogenesis. 2002;23(7):1095-102

9.- Liao DJ, Dickson RB. Roles of androgens in the development, growth, and carcinogenesis of the mammary gland. J Steroid Biochem Mol Biol. 2002 ;80(2):175-89

10.- The Endogenous Hormones and Breast Cancer Collaborative Group. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst 2002;94:606-16

11.- Howell A. Preliminary experience with pure antiestrogens. Clin Cancer Res. 2001;7(12 Suppl):4369s-4375s

12.- Dickson RB, Stancel GM. Estrogen receptor-mediated processes in normal and cancer cells. J Natl Cancer Inst Monogr. 2000;(27):135-45.

13.- O'Regan RM, Jordan VC. The evolution of tamoxifen therapy in breast cancer: selective oestrogen-receptor modulators and downregulators. Lancet Oncol. 2002;3(4):207-14.

14.- Thompson PA, Ambrosone C. Molecular epidemiology of genetic polymorphisms in estrogen metabolizing enzymes in human breast cancer. J Natl Cancer Inst Monogr. 2000;(27):125-34.

15.- Tomlinson IP. Mutations in normal breast tissue and breast tumours. Breast Cancer Res. 2001;3(5):299-303

16.- Liehr JG. Is estradiol a genotoxic mutagenic carcinogen? Endocr Rev. 2000;21(1):40-54.

17.- Osborne CK, Schiff R, Fuqua SA, Shou J. Estrogen receptor: current understanding of its activation and modulation. Clin Cancer Res. 2001;7(12 Suppl):4338s-4342s

18.- Lee AV, Cui X, Oesterreich S. Cross-talk among estrogen receptor, epidermal growth factor, and insulin-like growth factor signaling in breast cancer. Clin Cancer Res. 2001;7(12 Suppl):4429s-4435s

19.- Palmieri C, Cheng GJ, Saji S, Zelada-Hedman M, Warri A, Weihua Z, Van Noorden S, Wahlstrom T, Coombes RC, Warner M, Gustafsson JA. Estrogen receptor beta in breast cancer. Endocr Relat Cancer. 2002;9(1):1-13.

20.- Sugimura T. Nutrition and dietary carcinogens. Carcinogenesis. 2000;21(3):387-95.

21.- Kinsinger LS, Harris R, Woolf SH, Sox HC, Lohr KN. Chemoprevention of breast cancer: a summary of the evidence for the U.S.Preventive Services Task Force. Ann Intern Med. 2002 ;137(1):59-69.